Overview
- Quantitating and modeling physiologic processes in normal and diseased states in the central nervous system through the use of imaging
- Application and development of advanced MR imaging technologies (e.g., diffusion, perfusion and fMRI) as well as advanced image processing and analysis techniques
- Elucidating the functional unpinnings of cognitive impairment in early stage Alzheimer's disease
- Development of functional imaging biomarkers for early diagnosis and monitoring of dementia
- Functional MRI as an aid to preoperative planning in patients with potentially resectable brain lesions
- Application and development of advanced MR imaging technologies (e.g., diffusion, perfusion and fMRI) as well as advanced image processing and analysis techniques
- Elucidating the functional unpinnings of cognitive impairment in early stage Alzheimer's disease
- Development of functional imaging biomarkers for early diagnosis and monitoring of dementia
- Functional MRI as an aid to preoperative planning in patients with potentially resectable brain lesions
Current Appointments & Affiliations
Professor of Radiology
·
2014 - Present
Radiology, Neuroradiology,
Radiology
Director of Alzheimer's Disease Imaging Research Laboratory
·
2008 - Present
Radiology,
Clinical Science Departments
Member of the Center for Brain Imaging and Analysis
·
2004 - Present
Duke-UNC Brain Imaging and Analysis Center,
Institutes and Centers
Recent Publications
Artificial Intelligence-Assisted Detection of Amyloid-Related Imaging Abnormalities: Promise and Pitfalls.
Journal Article AJNR Am J Neuroradiol · February 3, 2026 The advent of anti-amyloid therapies (AATs) for Alzheimer disease (AD) has elevated the importance of MRI surveillance for amyloid-related imaging abnormalities (ARIA) such as microhemorrhages and siderosis (ARIA-H) and edema (ARIA-E). We report a literatu ... Full text Link to item CiteHippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials.
Journal Article CNS Drugs · December 1, 2025 Amyloid-plaque reduction is currently the only recognized surrogate outcome for Alzheimer's disease (AD) trials, allowing accelerated approval of plaque-clearing amyloid antibodies. However, plaque reduction does not facilitate the development of new non-p ... Full text Link to item CiteData-driven modeling of amyloid-β targeted antibodies for Alzheimer's disease.
Journal Article NPJ Syst Biol Appl · November 21, 2025 Alzheimer's disease (AD) is characterized by the accumulation of amyloid beta, which is strongly associated with disease progression and cognitive decline. Despite the approval of monoclonal antibodies targeting Aβ, optimizing treatment strategies while mi ... Full text Link to item CiteRecent Grants
Functional Networks of White Matter in Alzheimer's Disease and their Associations with Cognitive Decline
ResearchCo Investigator · Awarded by New Jersey Institute of Technology · 2024 - 2029Mathematical modeling, machine learning, neuroimaging, personalized medicine, optimal control, Alzheimer's disease.
ResearchPrincipal Investigator · Awarded by Sanofi US Services, Inc. · 2026 - 2026Collaborative Research: Personalized modeling of Alzheimer's disease
ResearchPrincipal Investigator · Awarded by National Science Foundation · 2021 - 2025View All Grants
Education, Training & Certifications
Rutgers University ·
1987
M.D.
Georgetown University ·
1983
B.S.